Cargando…
Current and Future Therapies for Pancreatic Ductal Adenocarcinoma
SIMPLE SUMMARY: Pancreatic cancer is the fourth leading cause of cancer-related mortality worldwide. The poor survival associated with this disease is due to delayed diagnosis, a lack of reliable biomarkers, and tumour resistance to treatment. Currently, surgery is the only curative treatment option...
Autores principales: | Sally, Áine, McGowan, Ryan, Finn, Karen, Moran, Brian Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139531/ https://www.ncbi.nlm.nih.gov/pubmed/35626020 http://dx.doi.org/10.3390/cancers14102417 |
Ejemplares similares
-
Circulating Nucleic Acids as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma
por: McGowan, Ryan, et al.
Publicado: (2022) -
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
por: Adamska, Aleksandra, et al.
Publicado: (2017) -
Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities
por: Jain, Aditi, et al.
Publicado: (2021) -
A Comprehensive Review of the Current and Future Role of the Microbiome in Pancreatic Ductal Adenocarcinoma
por: Merali, Nabeel, et al.
Publicado: (2022) -
Systemic therapy in pancreatic ductal adenocarcinomas (PDACs)—basis and current status
por: Ramaswamy, Anant, et al.
Publicado: (2022)